Meet ODD at these spring events

Unfortunately due to COVID-19 the events listed have been cancelled. We look forward to meeting you at future events. Oxford Drug Design will be presenting at four events over the next two months: Gordon Research Conference “Disruptive Antibiotics and non-Antibiotic Therapies to Combat Drug-Resistant Bacterial Infections”, 1-6 March, Lucca, Italy.  This is one of the […]

Oxford Drug Design wins UK-China AMR grant and boosts funding with investment from the Angel CoFund

Oxford University biotech spin-out receives over £2 million to take its drug discovery programme to the next level. Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised a combined £2.2M in funding from the Angel CoFund (ACF), o2h Ventures and other new investors, and grant funding […]

Oxford Drug Design presents at CDD 2019 Autumn Seminar Series

Oxford Drug Design recently attended an event at the Said Buisness School, in Oxford showcasing the latest developments of Collaborative Drug Discovery’s compound informatics system and ELN. Dr Michael Charlton spoke about our antibacterial projects and how Oxford Drug Design are integrating the collaborative features of CDD into our workflow.

Oxford Drug Design receives over £8m in grant and equity investment

Oxford Drug Design announced today success in securing funds, totalling over £8m, from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the UK Department of Health and Social Care Small Business Research Initiative (SBRI) and equity investment led by o2h Ventures. These funds will be used to advance our dual-target aminoacy-tRNA synthetase inhibitor (DaaRSi) project, which is […]

Dr Michael Charlton presents at CCG’s European User Group Meeting

Dr Michael Charlton recently presented our work in designing novel aminoacyl tRNA synthetase inhibitors at the Chemical Computing Group’s European User Group meeting in Oxford. Michael showed how we use CCG’s MOE modelling software in combination with our own ligand-based virtual screening methods to design novel inhibitors of leucyl tRNA synthetase.

Oxford Drug Design attends Fragments 2019

Marco Albanese recently presented a poster on using fragment-based approaches to discover compounds targeting the ATP-binding domain of bacterial histidine kinases at the 7th RSC-BMCS Fragment-based Drug Discovery meeting in Cambridge. Bacterial histidine kinases (HKs) are part of two-component systems (TCSs), the most widespread means by which bacteria sense and adapt to external and internal stimuli.  […]

Oxford Drug Design attends the 2nd SCI/RSC Symposium on Antimicrobial Drug Discovery

Prof. Paul Finn presented on a major cause of failure of antibacterial drug discovery projects, failure to accumulate sufficiently at the site of action to obtain an antibacterial effect, at the 2nd SCI/RSC Symposium on Antimicrobial Drug Discovery. Prof. Finn reviews attempts to address this issue through greater understanding the structural basis for penetration and the […]

Oxford Drug Design attends the JPI-AMR workshop in Oxford

Oxford Drug Design attended the JPI-AMR workshop on “Getting small drug-like molecules into Gram-negative bacteria”. This workshop provided an excellent opportunity to exchange ideas on the many factors influencing uptake and persistence of drug-like compounds into Gram-negative bacteria with others working in this field. Dr. Michael Charlton presented on our work to model bacterial penetration […]